Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a neoplasm with a dismal prognosis, whose incidence is increasing worldwide [1]. Only a minority of patients are amenable to multimodality treatment including surgery, and most are treated with chemotherapy during the course of their disease [2]. The combination of pemetrexed with cisplatin is the standard of care in the first-line setting [3]. Similar data have been reported with the raltitrexed/cisplatin combination, with weaker statistical significance [4]. (Source: Cancer Treatment Reviews)

from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=145549941&cid=c_409_6_f&fid=35390&url=http%3A%2F%2Fwww.cancertreatmentreviews.com%2Farticle%2FS0305-7372%2815%2900191-7%2Fabstract%3Frss%3Dyes